With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients stimulated rapid growth in Chinese demand for interventional cardiac operation and coronary stent. China's PCI (percutaneous coronary intervention) surgeries increased from 25,000 cases in 2002 to about 531,000 cases in 2012; the number of coronary stent implantation rose from 40,000 units in 2002 to approximately 640,000 units in 2012. In 2007-2012 China's cardiovascular stent market size grew at an AAGR of 20.3%.
 Your new post is loading...
Scoop.it!
Primary Percutaneous Coronary Intervention (PCI) has made huge leaps of improvement in the last two decades, with the ever goal being permanent sufficient flow in the coronary artery. From balloon angioplasty alone to subsequent Bare Metal Stent (BMS) implantation, measures have been made to achieve this aim. The introduction of the Drug Eluting Stent (DES) proved an ever better outcome: the antiproliferative drug coated struts seemed to cause an end to the last barrier of coronary reclosure: neo-intimal hyperproliferation inside the stent. However, contradicting results with regard to stent safety and effectiveness have been published and therefore we sought to compare the BMS with the DES in a real world STEMI-registry. Primarily, we aimed to investigate the DES ability in preventing target lesion revascularizations (TLR) as a result of in-stent restenosis. Our secondary endpoint was to compare both safety and effectiveness of both stent types. 
Scoop.it!
Dr. George Georgiou of the Nicosia General Hospital, Cyprus, discusses the challenges associated with drug eluting stents, including late catch-up phenomenon and late thrombosis.
Scoop.it!
Yock talks about the costs versus the charges of medical stents. A cynical approach is that the actual metal stents themselves cost 80-90 cents to make and their charge is about $1200. However, there is an enormous amount of R&D effort.
Scoop.it!
Dr. Zambahari of the Institut Jantung Nagara National Heart Institute in Kuala Lumpur, Malaysia, describes how the COMBO Dual Therapy Stent addresses the problem of late stent thrombosis associated with current monotherapy drug eluting stents.
Scoop.it!
Advancing the clinical practice of interventional cardiovascular medicine, India Medtronic today announces the availability of the U.S. Food and Drug Administration (FDA) approved Resolute Integrity™ Drug-Eluting Stent (DES) for the treatment of coronary artery disease (CAD) in India.
Scoop.it!
B Braun has been granted European CE Mark approval for its new Coroflex ISAR stent, for the treatment of stenoses in coronary arteries.
Scoop.it!
Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company's next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
Scoop.it!
Percutaneous coronary intervention with bare metal stents followed by a course of oral prednisone at immunosuppressive strength produces results comparable to that obtained with drug-eluting stents, an Italian Team has shown.
Scoop.it!
According to the company the trial will examine the “dissolving” heart device compared to Abbott’s drug-eluting stents in patients with coronary artery disease in Japan.
Scoop.it!
Using bare metal stents for many low-risk patients could save more than $200 million annually.
|
Curated by Beeyond
BEEYOND is a consulting company in the field of disruptive innovation, accompanying established companies on out-of-the-core growth strategy, from creation of new concepts to product launch. Reach us at: contact@beeyond.fr.
Other Topics
#dotdot, the community internet
Aidants
Aston-Martin
Augmented & Virtual Reality
Blue Ocean Strategy
Brain Computer Interfaces & connected medical devices
Consumer Digital Health
Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz
Critical Limb-Threatening Ischemia (CLTI)
Daily realities of diabetic patients
Fashion & technology
Healthcare: reloaded...
High level trending in...
In-Vitro Diagnostic
Innovating to what's next...
Instrumental cosmetics
Interventional Cardiology
Intra-Dermal drug delivery: Opportunities and Challenges?
Local delivery for Gene Directed Enzyme Prodrug Therapy
Engineered MSCs with suicide genes delivered intra-arterially to treat various cancers. Local delivery bypasses homing issues that plagued prior GDEPT programs.
Metabolic Activation Therapy
Multiple sclerosis
Neurovascular Intervention
Nudges
Peritoneal dialysis
Solid tumors: latest on treaments and research pathways
glioblastoma, craniopharyngioma...
Tailored Expertise Sourcing & Market Intelligence in Global Consulting
The future of e-cigarette
The Revolution Of The Car Industry
Track & Trace
Transcatheter Treatment of Mitral Regurgitation
|
